SLC5A2 and hydrops fetalis: Among 12,251 patients from the DELIVER and EMPEROR-Preserved trials, there was a significant reduction in the primary endpoint for composite CV death or first hospitalization for HF for patients receiving an SGLT2 inhibitor compared to placebo (HR, 0.80; 95% CI [0.73–0.87]) (Figure 4).